CHEMELLO, LILIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.041
AS - Asia 7.226
EU - Europa 4.395
AF - Africa 2.074
SA - Sud America 1.899
OC - Oceania 218
Continente sconosciuto - Info sul continente non disponibili 109
Totale 29.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.998
SG - Singapore 2.549
CN - Cina 1.242
BR - Brasile 1.178
HK - Hong Kong 963
FI - Finlandia 540
DE - Germania 516
VN - Vietnam 500
PL - Polonia 421
IT - Italia 350
SE - Svezia 260
RU - Federazione Russa 194
FR - Francia 178
UA - Ucraina 175
AR - Argentina 128
GB - Regno Unito 126
TR - Turchia 102
ZA - Sudafrica 99
EC - Ecuador 94
IE - Irlanda 93
MX - Messico 90
AT - Austria 88
IN - India 88
NL - Olanda 88
CO - Colombia 81
IQ - Iraq 79
ID - Indonesia 78
PE - Perù 78
NP - Nepal 77
MA - Marocco 76
CI - Costa d'Avorio 75
ES - Italia 71
MN - Mongolia 71
JP - Giappone 69
LC - Santa Lucia 69
SI - Slovenia 69
PY - Paraguay 67
MK - Macedonia 66
NO - Norvegia 66
SA - Arabia Saudita 65
AE - Emirati Arabi Uniti 64
KG - Kirghizistan 64
PK - Pakistan 64
UZ - Uzbekistan 63
ZM - Zambia 63
JO - Giordania 62
LB - Libano 62
RO - Romania 62
AO - Angola 61
CZ - Repubblica Ceca 61
DZ - Algeria 60
PS - Palestinian Territory 60
TT - Trinidad e Tobago 60
UY - Uruguay 60
JM - Giamaica 59
AL - Albania 58
BZ - Belize 58
CL - Cile 58
GT - Guatemala 58
KR - Corea 58
PA - Panama 58
TN - Tunisia 58
EG - Egitto 57
AU - Australia 56
BG - Bulgaria 56
CV - Capo Verde 56
CW - ???statistics.table.value.countryCode.CW??? 56
ET - Etiopia 56
KZ - Kazakistan 56
MZ - Mozambico 56
PR - Porto Rico 56
ZW - Zimbabwe 56
CG - Congo 54
AZ - Azerbaigian 53
BF - Burkina Faso 53
DO - Repubblica Dominicana 53
GR - Grecia 53
IS - Islanda 53
VE - Venezuela 53
GA - Gabon 52
GN - Guinea 52
MY - Malesia 52
NI - Nicaragua 52
BE - Belgio 51
BO - Bolivia 51
GM - Gambi 51
HN - Honduras 51
IR - Iran 51
ML - Mali 51
PT - Portogallo 51
RS - Serbia 51
UG - Uganda 51
BY - Bielorussia 50
CR - Costa Rica 50
GF - Guiana Francese 50
HR - Croazia 50
IL - Israele 50
SK - Slovacchia (Repubblica Slovacca) 50
BB - Barbados 49
LV - Lettonia 49
Totale 27.546
Salva come PNG Salva come JPEG
Città #
Fairfield 1.641
Singapore 1.303
Jacksonville 1.236
Ashburn 1.073
Woodbridge 945
Hong Kong 912
Houston 865
Chandler 816
Wilmington 772
Cambridge 600
Seattle 539
Ann Arbor 472
Princeton 410
Boardman 389
Bytom 351
Medford 230
Santa Clara 222
Beijing 217
San Diego 207
Nanjing 190
Helsinki 187
Ho Chi Minh City 163
Los Angeles 131
Munich 121
Roxbury 118
São Paulo 97
Hanoi 90
Buffalo 85
Dublin 84
Guangzhou 83
Des Moines 74
New York 74
Ulan Bator 69
Abidjan 68
Castries 67
Chicago 66
Shenyang 66
Dong Ket 64
Amman 60
Hebei 60
Lusaka 59
Nanchang 59
Bishkek 57
Hefei 56
Tashkent 56
Jiaxing 54
Vienna 53
Harare 52
Libreville 52
Lima 52
Luanda 52
Padova 52
Panama City 52
Baku 51
Montevideo 51
Changsha 50
Conakry 50
Redondo Beach 50
Bamako 49
Kampala 49
Managua 49
Willemstad 47
Bridgetown 46
Maputo 45
Norwalk 44
Addis Ababa 43
Dakar 43
Dushanbe 43
Cotonou 42
Antananarivo 41
Minsk 41
Reykjavik 41
Vientiane 41
Accra 40
Praia 40
Riga 40
Turku 40
Nassau 39
Ouagadougou 39
Tianjin 39
Skopje 38
Guayaquil 37
Kigali 37
Ljubljana 37
Phnom Penh 37
Cayenne 36
Milan 36
Nairobi 36
Nuremberg 36
Pristina 36
Tirana 36
Podgorica 35
Andorra la Vella 34
Djibouti 34
Gaborone 34
Guatemala City 34
Havana 34
Lilongwe 34
Nouakchott 34
Noumea 34
Totale 17.825
Salva come PNG Salva come JPEG
Nome #
Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study 241
Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. 205
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 203
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort 200
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. 199
Cognitive effects of long-term interferon treatment for chronic viral hepatitis 193
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. 188
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 184
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 179
Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma 174
Liver stellate cells in chronic viral hepatitis : the effect of interferon therapy. 172
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 170
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 170
ANTIBODY TO THE POLYALBUMIN (pHSA) RECEPTOR ON HEPATITIS B VIRUS IN ACUTE INFECTION AND IN VACCINE RECIPIENTS 169
Hepatitis C Virus Reinfection in Liver Transplant Patients: Evaluation of Liver Damage Progression with Echo-Color Doppler 169
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 169
Prognostic value of liver and spleen stiffness in patients with fontan associated liver disease (Fald): A case series with histopathologic comparison 168
HEPATITIS C VIRUS SEROTYPES AND LIVER PATHOLOGY 164
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. 164
SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection 161
Profiles of HCV core protein and viremia in chronic hepatitis C: Possible protective role of core antigen in liver damage 160
Kinetic of virological response during PEG-IFNs in chronic hepatitis C. 158
HEPATITIS C VIRUS RNA PROFILES IN CHRONICALLY INFECTED INDIVIDUALS: DO THEY RELATE TO DISEASE ACTIVITY? 156
Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. 156
Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C 155
Liver Fibrosis and Steatosis in Alstrom Syndrome: A Genetic Model for Metabolic Syndrome 153
Chronic evolution of acute hepatitis type B: prevalence and predictive markers 152
Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color doppler. 152
HEART RATE VARIABILITY PARALLELS CHANGES IN PSYCHIATRIC SCALES IN INTERFERON-TREATED PATIENTS WITH CHRONIC HEPATITIS 151
HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND HEPATITIS-C PATHOLOGY 148
Acute hepatitis C virus infection in a nurse trainee following a needlestick injury 147
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 146
Role of transient elastography to stage fontan-associated liver disease (Fald) in adults with single ventricle congenital heart disease correction 146
In-Hospital Screening Campaign Against Hepatitis C Could Be Effective for Identifying More Patients Who Still Need Treatment 145
Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C 145
A model to predict long-term sustained response to interferon therapy in chronic hepatitis C 145
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 145
Serum hepatitis B virus DNA in acute hepatitis type B 144
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients. 144
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 144
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 143
Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. 143
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. 141
Surgical management of failing Fontan circulation: Results from 30 cases with 285 patient-years follow-up 140
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels 138
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 138
PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND NON INVASIVE MARKERS OF LIVER FIBROSIS IN PRIMARY BILIARY CIRRHOSIS 137
Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. 135
Natural history of hepatitis C. 135
Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma 134
Alterazioni neurovascolari nell’epatite cronica C: uno studio caso-controllo 133
Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer 133
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals 133
Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population 132
Therapy of hepatitis C: re-treatment with alpha interferon. 132
Serum miRNA are promising biomarkers for the detection of early hepatocellular carcinoma after treatment with direct-acting antivirals 132
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 131
Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa‐2A interferon 130
Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C 130
OUTCOME OF ACUTE HEPATITIS C AND ROLE OF ALPHA INTERFERON THERAPY 130
Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. 130
The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence 129
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. 129
Latent hepatitis B virus infection in childhood hepatocellular carcinoma. Analysis by polymerase chain reaction. 129
A COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS OF VARICEAL BLEEDING STARTING FROM SMALL ESOPHAGEAL VARICES COMPARED TO SURVEILLANCE AND TREATMENT STARTING FROM LARGE ONES 126
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 126
Heart rate variability parallels changes in psychiatric scales in interferon-treated patients with chronic hepatitis. 124
Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. 124
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. 122
METABOLIC SYNDROME INDUCES A MORE RAPID PROGRESSION OF FIBROSIS IN PRIMARY BILIARY CIRRHOSIS IN EARLY STAGE 121
The cognitive effects of long-term interferon treatment for chronic viral hepatitis 120
NATURAL KILLER ACTIVITY IN PATIENTS WITH ACUTE VIRAL HEPATITIS 119
DEREGOLAZIONE DELL’ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) NEI LINFOCITI B IN PAZIENTI INFETTI DA HCV 119
RELATIONSHIP BETWEEN HBcAg IN SERUM AND LIVER AND HBV REPLICATION IN PATIENTS WITH HBsAg POSITIVE CHRONIC LIVER DISEASE 119
Natural killer activity in patients with acute viral hepatitis 118
Chonic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. 117
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 117
ESPRESSIONE DELLA SERPINA SCCA IN CELLULE MONONUCLEATE DI SANGUE PERIFERICO IN PAZIENTI CO INFEZIONE CRONICA DA HCV 117
Validation of a new sonographic parameter (liver/kidney ratio of greys intensity of digital images) for diagnosis and quantification of liver steatosis 117
Anti-interferon antibodies during interferon therapy for chronic hepatitis C. 116
A MODEL TO PREDICT SUSTAINED RESPONSE TO THERAPY AND TO OPTIMIZE THE DOSE OF INTERFERON IN CHRONIC HEPATITIS C 116
BIOLOGIA MOLECOLARE APPLICATA AL VIRUS DELL'EPATITE B. STUDIO DEL DNA VIRALE NEL SIERO E NEL FEGATO E CORRELAZIONE CLINICA 116
COMPARISON OF THRICE WEEKLY VS DAILY HUMAN LEUCOCYTE INTERFERON-ALPHA THERAPY FOR CHRONIC HEPATITIS C. TVVH STUDY GROUP. 115
PREDICTIVE MARKERS OF CHRONICITY IN ACUTE HEPATITIS TYPE B 115
EVIDENCE OF HEPATITIS B VIRUS INFECTION IN CHRONIC HEPATITIS HBsAg NEGATIVE BY CONVENTIONAL ASSAYS 115
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 114
SERUM HBV-DNA IN ANTI-HBE POSITIVE PATIENTS DETECTED BY FILTER AND LIQUID-PHASE HYBRIDIZATION ASSAYS 114
RESPONSE TO RIBAVIRIN, TO INTERFERON AND TO A COMBINATION OF BOTH IN PATIENTS WITH CHRONIC HEPATITIS C AND ITS RELATION TO HCV GENOTYPES 114
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 113
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay. 113
Hepatitis C serotype and response to interferon therapy. 113
Interferon-ribavirin combination therapy for chronic hepatitis C. 112
Espressione della serpina SCCA in cellule mononucleate di sangue periferico in pazienti con infezione cronica da HCV 112
Changes in serum tryptophan during antiviral therapy with recombinant alfa-interferon in chronic hepatitis C 112
ALTERAZIONI DELL'ATTIVITA' NATURAL KILLER IN CORSO DI INFEZIONE DA VIRUS EPATITICI 112
SCCA EXPRESSION IN PBMCs IN PATIENTS WITH CHRONIC HEPATITIS C 112
Comparison of thrice weekly vs daily human leucocyte interferon-alfa therapy for chronic hepatitis C. 111
Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. 111
RADIOIMMUNOASSAY FOR HEPATITIS B SURFACE ANTIGEN IN SERA OF CHILDREN WITH ACUTE LEUKEMIA 111
Monoclonal radioimmunoassay for hepatitis B surface antigen in sera of children with acute leukemia. 111
Totale 14.035
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.612
article - articoli 68.448
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 717
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.457
Totale 162.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.325 0 0 0 0 0 255 37 149 330 154 174 226
2021/20222.678 42 481 200 241 78 150 112 262 139 52 305 616
2022/20231.972 600 160 62 145 315 233 8 115 194 23 100 17
2023/2024817 38 102 81 51 36 74 48 29 21 22 124 191
2024/20255.219 4 308 197 135 715 76 182 321 555 231 1.030 1.465
2025/202611.432 642 1.931 3.488 3.358 1.587 426 0 0 0 0 0 0
Totale 30.038